Advanced search
Publication Cover
Hematology Volume 26, 2021 - Issue 1
Submit an article Journal homepage
2,554
Views
1
CrossRef citations to date
0
Altmetric
Articles

Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma

Satoshi Yoshiharaa Department of Hematology, Hyogo College of Medicine Hospital, Hyogo, Japan;b Department of Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine Hospital, Hyogo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8537-2422View further author information
ORCID Icon,
Kyoko Yoshiharaa Department of Hematology, Hyogo College of Medicine Hospital, Hyogo, JapanView further author information
,
Yoshifumi Shimizuc Department of Hematology, Takarazuka City Hospital, Hyogo, JapanView further author information
,
Takehito Imadoc Department of Hematology, Takarazuka City Hospital, Hyogo, JapanView further author information
,
Hiroyuki Takatsukad Department of Hematology, Amagasaki Chuo Hospital, Hyogo, JapanView further author information
,
Hiroyuki Kawamotoe Department of Hematology, Uegahara Hospital, Hyogo, JapanView further author information
,
Mahito Misawaf Department of Hematology, Ako Central Hospital, Hyogo, JapanView further author information
,
Hideki Ifukud Department of Hematology, Amagasaki Chuo Hospital, Hyogo, JapanView further author information
,
Yokiko Ohee Department of Hematology, Uegahara Hospital, Hyogo, JapanView further author information
,
Masaya Okadaa Department of Hematology, Hyogo College of Medicine Hospital, Hyogo, JapanView further author information
&
Yoshihiro Fujimoria Department of Hematology, Hyogo College of Medicine Hospital, Hyogo, Japan;b Department of Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine Hospital, Hyogo, Japan;e Department of Hematology, Uegahara Hospital, Hyogo, JapanView further author information
 show all
Pages 388-392 | Published online: 17 May 2021

References

  • van de Velde HJ, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92(10):1399–1406.
  • Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99–02 and 99–04 trials. J Clin Oncol. 2009;27(34):5720–5726.
  • Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32(25):2712–2717.
  • Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
  • Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
  • Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
  • Takamatsu H, Yoroidaka T, Fujisawa M, et al. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol. 2019;109(4):377–381.
  • Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):2035–2042.
  • Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(6):718–723.
  • Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114(9):1729–1735.
  • Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337–1345.
  • Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784–792.
  • Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19(17):3771–3779.
  • Takamatsu H, Takezako N, Zheng J, et al. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol. 2017;28(10):2503–2510.
  • Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010;115(3):605–614.
  • Li S, Fu J, Ma H, et al. Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia. 2013;27(6):1407–1411.
  • Dosani T, Covut F, Pinto R, et al. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leuk Lymphoma. 2019;60(9):2199–2206.
  • Partanen A, Valtola J, Silvennoinen R, et al. Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study. Transfusion. 2017;57(10):2366–2372.
  • Tageja N, Korde N, Kazandjian D, et al. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. Bone Marrow Transplant. 2018;53(11):1445–1449.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.